Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Postoperative chemoradiotherapy is the recommended standard therapy for patients with locally advanced rectal cancer. In recent years, encouraging results with preoperative radiotherapy have been reported. We compared preoperative chemoradiotherapy with postoperative chemoradiotherapy for locally advanced rectal cancer. METHODS: We randomly assigned patients with clinical stage T3 or T4 or node-positive disease to receive either preoperative or postoperative chemoradiotherapy. The preoperative treatment consisted of 5040 cGy delivered in fractions of 180 cGy per day, five days per week, and fluorouracil, given in a 120-hour continuous intravenous infusion at a dose of 1000 mg per square meter of body-surface area per day during the first and fifth weeks of radiotherapy. Surgery was performed six weeks after the completion of chemoradiotherapy. One month after surgery, four five-day cycles of fluorouracil (500 mg per square meter per day) were given. Chemoradiotherapy was identical in the postoperative-treatment group, except for the delivery of a boost of 540 cGy. The primary end point was overall survival. RESULTS: Four hundred twenty-one patients were randomly assigned to receive preoperative chemoradiotherapy and 402 patients to receive postoperative chemoradiotherapy. The overall five-year survival rates were 76 percent and 74 percent, respectively (P=0.80). The five-year cumulative incidence of local relapse was 6 percent for patients assigned to preoperative chemoradiotherapy and 13 percent in the postoperative-treatment group (P=0.006). Grade 3 or 4 acute toxic effects occurred in 27 percent of the patients in the preoperative-treatment group, as compared with 40 percent of the patients in the postoperative-treatment group (P=0.001); the corresponding rates of long-term toxic effects were 14 percent and 24 percent, respectively (P=0.01). CONCLUSIONS: Preoperative chemoradiotherapy, as compared with postoperative chemoradiotherapy, improved local control and was associated with reduced toxicity but did not improve overall survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among the patients in whom abdominoperineal resection (APR) was considered necessary at the time of enrollment, the percentage of patients in whom sphincter preservation was possible was significantly higher in the preoperative chemoradiotherapy group [119].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
In the citing paper
“there was no significant difference in the 5-year survival rate”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
In the citing paper
“but the local recurrence rate and incidence of grade 3 or higher adverse events were significantly lower in the preoperative chemoradiotherapy group.”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
Citations
Cites
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer
Kapiteijn, E., Marijnen, C. A. M., Nagtegaal, I. D., Putter, H., Steup, W. H., Wiggers, T., Rutten, H. J. T., Pahlman, L., Glimelius, B., van Krieken, J. H. J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010580 · Cited by 4,205
Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer
(1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361402 · Cited by 2,517
Effective Surgical Adjuvant Therapy for High-Risk Rectal Carcinoma
Krook, J. E., Moertel, C. G., Gunderson, L. L., Wieand, H. S., Collins, R. T., Beart, R. W., Kubista, T. P., Poon, M. A., Meyers, W. C., Mailliard, J. A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103143241101 · Cited by 1,879
Statistical methods in cancer research. Vol. 1. The analysis of case-control studies
(1983) · Food and Chemical Toxicology · doi:10.1016/0278-6915(83)90281-8 · Cited by 1,716
Prolongation of the Disease-Free Interval in Surgically Treated Rectal Carcinoma
Gastrointestinal Tumor Study Group (1985) · New England Journal of Medicine · doi:10.1056/nejm198506063122301 · Cited by 1,130
(2001) · The Lancet · doi:10.1016/s0140-6736(01)06409-1 · Cited by 870
Preoperative Radiotherapy for Resectable Rectal Cancer: A Meta-analysis
Cammà, C., Giunta, M., Fiorica, F., Pagliaro, L., Craxì, A., & Cottone, M. (2000) · JAMA · doi:10.1001/jama.284.8.1008 · Cited by 754
NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer
(1990) · JAMA · doi:10.1001/jama.264.11.1444 · Cited by 394
Hyams, D. M., Mamounas, E. P., Petrelli, N., Rockette, H., Jones, J., Wieand, S. H., Deutsch, M., Wickerham, L. D., Fisher, B., & Wolmark, N. (1997) · Diseases of the Colon & Rectum · doi:10.1007/bf02054976 · Cited by 360
Research works printed but not linked: 3
- Seegenschmiedt MH, 1993, Strahlenther Onkol, 169, 83
- Pichlmaier H, 1994, Chirurg, 65, 411
- Hermanek P. What can the pathologist tell the surgeon about rectal cancer resection? In: Scholefield JH, ed. Challenges in colorectal cancer. Oxford, England: Blackwell, 2000:81-90.
Cited by
Colorectal cancer statistics, 2017
Siegel, R. L., Miller, K. D., Fedewa, S. A., Ahnen, D. J., Meester, R. G. S., Barzi, A., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21395 · Cited by 3,806
Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
Bosset, J.-F., Collette, L., Calais, G., Mineur, L., Maingon, P., Radosevic-Jelic, L., Daban, A., Bardet, E., Beny, A., & Ollier, J.-C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060829 · Cited by 2,688
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467
“1 3 cantly higher in the preoperative chemoradiotherapy group [119].”
BackgroundSauer, R., Liersch, T., Merkel, S., Fietkau, R., Hohenberger, W., Hess, C., Becker, H., Raab, H.-R., Villanueva, M.-T., Witzigmann, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1836 · Cited by 2,095
“Compared with postoperative CRT, the preoperative approach was superior in terms of treatment compliance, toxicity, downstaging, sphincter preservation in patients judged by the surgeon to require an abdominoperineal resection, and 5-year local control.(5) Given these advantages, preoperative CRT has become the prefer…”
Self-citationRectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Glynne-Jones, R., Wyrwicz, L., Tiret, E., Brown, G., Rödel, C., Cervantes, A., & Arnold, D. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx224 · Cited by 2,046
“0 Gy/fraction) or SCPRT has better outcomes than postoperative CRT [87, 88].”
Self-citationMaas, M., Nelemans, P. J., Valentini, V., Das, P., Rödel, C., Kuo, L.-J., Calvo, F. A., García-Aguilar, J., Glynne-Jones, R., Haustermans, K., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70172-8 · Cited by 1,945
Self-citationHashiguchi, Y., Muro, K., Saito, Y., Ito, Y., Ajioka, Y., Hamaguchi, T., Hasegawa, K., Hotta, K., Ishida, H., Ishiguro, M., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01485-z · Cited by 1,922
“1 3 significantly higher in the preoperative chemo‐ radiotherapy group [241].”
BackgroundRectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Glimelius, B., Tiret, E., Cervantes, A., & Arnold, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt240 · Cited by 1,783
Gérard, J.-P., Conroy, T., Bonnetain, F., Bouché, O., Chapet, O., Closon-Dejardin, M.-T., Untereiner, M., Leduc, B., Francois, É., Maurel, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7629 · Cited by 1,731
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Kuipers, E. J., Grady, W. M., Lieberman, D., Seufferlein, T., Sung, J. J., Boelens, P. G., van de Velde, C. J. H., & Watanabe, T. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.65 · Cited by 1,563
Hohenberger, W., Weber, K., Matzel, K., Papadopoulos, T., & Merkel, S. (2009) · Colorectal Disease · doi:10.1111/j.1463-1318.2008.01735.x · Cited by 1,636
Self-citationBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Schmoll, H. J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C. J., Balmana, J., Regula, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,510
Sebag-Montefiore, D., Stephens, R. J., Steele, R., Monson, J., Grieve, R., Khanna, S., Quirke, P., Couture, J., de Metz, C., Myint, A. S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60484-0 · Cited by 1,493
Cunningham, D., Atkin, W., Lenz, H.-J., Lynch, H. T., Minsky, B., Nordlinger, B., & Starling, N. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60353-4 · Cited by 1,351
Bujko, K., Nowacki, M. P., Nasierowska-Guttmejer, A., Michalski, W., Bebenek, M., & Kryj, M. (2006) · British Journal of Surgery · doi:10.1002/bjs.5506 · Cited by 1,244
Prognostic Significance of Tumor Regression After Preoperative Chemoradiotherapy for Rectal Cancer
Rödel, C., Martus, P., Papadoupolos, T., Füzesi, L., Klimpfinger, M., Fietkau, R., Liersch, T., Hohenberger, W., Raab, R., Sauer, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.1329 · Cited by 1,215
“Radiation techniques have been described in more detail elsewhere.(3,12) During the first and fifth weeks of radiotherapy, fluorouracil was administered as a 120-hour continuous infusion at a dose of 1,000 mg/m(2)/d.”
BackgroundMethodSelf-citationPeeters, K. C. M. J., Marijnen, C. A. M., Nagtegaal, I. D., Kranenbarg, E. K., Putter, H., Wiggers, T., Rutten, H., Pahlman, L., Glimelius, B., Leer, J. W., et al. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000257358.56863.ce · Cited by 1,191
“80).(23) Although trial results should be compared with care due to differences in case mix, it has to be noted that survival rates in the German study appear more favorable, despite the advanced stage of disease at presentation.”
ResultWeitz, J., Koch, M., Debus, J., Höhler, T., Galle, P. R., & Büchler, M. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17706-x · Cited by 1,098
Versteijne, E., Suker, M., Groothuis, K., Akkermans-Vogelaar, J. M., Besselink, M. G., Bonsing, B. A., Buijsen, J., Busch, O. R., Creemers, G.-J. M., van Dam, R. M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02274 · Cited by 1,082
Quirke, P., Steele, R., Monson, J., Grieve, R., Khanna, S., Couture, J., O'Callaghan, C., Myint, A. S., Bessell, E., Thompson, L. C., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60485-2 · Cited by 1,053
Kang, S.-B., Park, J. W., Jeong, S.-Y., Nam, B. H., Choi, H. S., Kim, D.-W., Lim, S.-B., Lee, T.-G., Kim, D. Y., Kim, J.-S., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70131-5 · Cited by 1,019
What Is the Role for the Circumferential Margin in the Modern Treatment of Rectal Cancer?
Nagtegaal, I. D., & Quirke, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7027 · Cited by 1,006
Liu, Z., Wang, S., Dong, D., Wei, J., Fang, C., Zhou, X., Sun, K., Li, L., Li, B., Wang, M., et al. (2019) · Theranostics · doi:10.7150/thno.30309 · Cited by 967
“Although treatment may improve survival, it has not proven to improve the DFS of patients with locally advanced rectal cancer [13, 173, 174].”
BackgroundMethodRectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Cederquist, L., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Engstrom, P. F., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0061 · Cited by 944
Roh, M. S., Colangelo, L. H., O'Connell, M. J., Yothers, G., Deutsch, M., Allegra, C. J., Kahlenberg, M. S., Baez-Diaz, L., Ursiny, C. S., Petrelli, N. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.0467 · Cited by 933
“In the German Rectal Cancer Study Group, the 5-year DFS was 68% for the preoperative and 65% for the postoperative group.(9) The radiotherapy dose in the NSABP R-03 study was similar to that in the German study, but the chemotherapy regimens were different.”
BackgroundMethodResultInfluentialMERCURY Study Group (2006) · BMJ · doi:10.1136/bmj.38937.646400.55 · Cited by 923
“…the optimal surgical technique of total mesorectal excision can cure early stage localised rectal cancer, 3 4 it is now evident that preoperative radiotherapy or chemoradiotherapy 5 may facilitate successful surgical excision and therefore improve outcome in patients with more extensive disease.”
BackgroundNgan, S. Y., Burmeister, B., Fisher, R. J., Solomon, M., Goldstein, D., Joseph, D., Ackland, S. P., Schache, D., McClure, B., McLachlan, S.-A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.9597 · Cited by 921
Jeong, S.-Y., Park, J. W., Nam, B. H., Kim, S., Kang, S.-B., Lim, S.-B., Choi, H. S., Kim, D.-W., Chang, H. J., Kim, D. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70205-0 · Cited by 888
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Azad, N., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Garrido-Laguna, I., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0051 · Cited by 827
Aschele, C., Cionini, L., Lonardi, S., Pinto, C., Cordio, S., Rosati, G., Artale, S., Tagliagambe, A., Ambrosini, G., Rosetti, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4911 · Cited by 763
Gérard, J.-P., Azria, D., Gourgou-Bourgade, S., Martel-Laffay, I., Hennequin, C., Etienne, P.-L., Vendrely, V., François, E., de La Roche, G., Bouché, O., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8376 · Cited by 747
Bosset, J.-F., Calais, G., Mineur, L., Maingon, P., Stojanovic-Rundic, S., Bensadoun, R.-J., Bardet, E., Beny, A., Ollier, J.-C., Bolla, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70599-0 · Cited by 730
Rödel, C., Graeven, U., Fietkau, R., Hohenberger, W., Hothorn, T., Arnold, D., Hofheinz, R.-D., Ghadimi, M., Wolff, H. A., Lang-Welzenbach, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00159-x · Cited by 726
Self-citationJapanese Society for Cancer of the Colon and Rectum, Watanabe, T., Itabashi, M., Shimada, Y., Tanaka, S., Ito, Y., Ajioka, Y., Hamaguchi, T., Hyodo, I., Igarashi, M., et al. (2012) · International Journal of Clinical Oncology · doi:10.1007/s10147-011-0315-2 · Cited by 700
Rödel, C., Liersch, T., Becker, H., Fietkau, R., Hohenberger, W., Hothorn, T., Graeven, U., Arnold, D., Lang-Welzenbach, M., Raab, H.-R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70187-0 · Cited by 696
Self-citationGarcia-Aguilar, J., Chow, O. S., Smith, D. D., Marcet, J. E., Cataldo, P. A., Varma, M. G., Kumar, A. S., Oommen, S., Coutsoftides, T., Hunt, S. R., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00004-2 · Cited by 697
Marijnen, C. A. M., van de Velde, C. J. H., Putter, H., van den Brink, M., Maas, C. P., Martijn, H., Rutten, H. J., Wiggers, T., Kranenbarg, E. K., Leer, J.-W. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.256 · Cited by 650
Taylor, F. G. M., Quirke, P., Heald, R. J., Moran, B. J., Blomqvist, L., Swift, I. R., Sebag-Montefiore, D., Tekkis, P., & Brown, G. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3258 · Cited by 633
“As with other solid tumors, preoperative treatment can be beneficial, but optimal patient selection for treatment is also important.(1,2) Tumor within 1 mm of the surgical circumferential resection margin (CRM), as judged by the pathologist, is a crucial, potentially preventable factor that predicts both local recurre…”
BackgroundMethodMartin, S. T., Heneghan, H. M., & Winter, D. C. (2012) · British Journal of Surgery · doi:10.1002/bjs.8702 · Cited by 637
Erlandsson, J., Holm, T., Pettersson, D., Berglund, Å., Cedermark, B., Radu, C., Johansson, H., Machado, M., Hjern, F., Hallböök, O., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30086-4 · Cited by 624
Systematic Review and Meta-Analysis of the Role of Defunctioning Stoma in Low Rectal Cancer Surgery
Hüser, N., Michalski, C. W., Erkan, M., Schuster, T., Rosenberg, R., Kleeff, J., & Friess, H. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e318176bf65 · Cited by 616
Bosset, J.-F., Calais, G., Mineur, L., Maingon, P., Radosevic-Jelic, L., Daban, A., Bardet, E., Beny, A., Briffaux, A., & Collette, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.113 · Cited by 594
Watanabe, T., Itabashi, M., Shimada, Y., Tanaka, S., Ito, Y., Ajioka, Y., Hamaguchi, T., Hyodo, I., Igarashi, M., Ishida, H., et al. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-015-0801-z · Cited by 590
Al-Sukhni, E., Milot, L., Fruitman, M., Beyene, J., Victor, J. C., Schmocker, S., Brown, G., McLeod, R., & Kennedy, E. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2210-5 · Cited by 576
“The optimal time to administer CRT was investigated in a German trial (36) which compared local recurrence and overall survival in Stage II and III rectal cancer patients randomized to receive CRT before or after TME surgery.”
BackgroundInfluentialGlobal trends in colorectal cancer mortality: projections to the year 2035
Araghi, M., Soerjomataram, I., Jenkins, M., Brierley, J., Morris, E., Bray, F., & Arnold, M. (2019) · International Journal of Cancer · doi:10.1002/ijc.32055 · Cited by 556
“For rectal cancer, the major treatment advances are a result of improved surgical techniques often combined with preoperative chemo-radiation therapy or radiation alone.(47,48) In many less developed countries, the lack of access to adjuvant therapy has been previously reported.”
BackgroundPractice Parameters for the Management of Rectal Cancer (Revised)
Monson, J. R. T., Weiser, M. R., Buie, W. D., Chang, G. J., Rafferty, J. F., Buie, W. D., Rafferty, J., Guillem, J., Boushey, R., Chang, G., et al. (2013) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e31828cb66c · Cited by 563
Valentini, V., van Stiphout, R. G. P. M., Lammering, G., Gambacorta, M. A., Barba, M. C., Bebenek, M., Bonnetain, F., Bosset, J.-F., Bujko, K., Cionini, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.1595 · Cited by 563
Self-citationRadiation Dose–Volume Effects in the Stomach and Small Bowel
Kavanagh, B. D., Pan, C. C., Dawson, L. A., Das, S. K., Li, X. A., Ten Haken, R. K., & Miften, M. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.05.071 · Cited by 550
“In the Phase III German Rectal Cancer Study Group (35), pre- vs. postoperative pelvic RT (50.4 Gy in 28 fractions) were associated with a 9% vs. 15% rate of long term GI toxicity (p = 0.07).”
BackgroundInfluentialMyerson, R. J., Garofalo, M. C., El Naqa, I., Abrams, R. A., Apte, A., Bosch, W. R., Das, P., Gunderson, L. L., Hong, T. S., Kim, J. J. J., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.08.070 · Cited by 524
MRI of Rectal Cancer: Tumor Staging, Imaging Techniques, and Management
Horvat, N., Carlos Tavares Rocha, C., Clemente Oliveira, B., Petkovska, I., & Gollub, M. J. (2019) · RadioGraphics · doi:10.1148/rg.2019180114 · Cited by 509
Postoperative Complications Following Surgery for Rectal Cancer
Paun, B. C., Cassie, S., MacLean, A. R., Dixon, E., & Buie, W. D. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181dae4ed · Cited by 515
Hofheinz, R.-D., Wenz, F., Post, S., Matzdorff, A., Laechelt, S., Hartmann, J. T., Müller, L., Link, H., Moehler, M., Kettner, E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70116-x · Cited by 509
Willett, C. G., Duda, D. G., di Tomaso, E., Boucher, Y., Ancukiewicz, M., Sahani, D. V., Lahdenranta, J., Chung, D. C., Fischman, A. J., Lauwers, G. Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1771 · Cited by 508
“Although patient numbers are small in this study, these results compare favorably to the overall results of 415 patients randomly assigned to preoperative chemoradiotherapy in the German Rectal Cancer Study Group.(10) Examination of early and postoperative adverse effects of the combined treatment suggested a good saf…”
ResultSystemic Treatment of Colorectal Cancer
Wolpin, B. M., & Mayer, R. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.098 · Cited by 504
Preoperative Treatment of Locally Advanced Rectal Cancer
Schrag, D., Shi, Q., Weiser, M. R., Gollub, M. J., Saltz, L. B., Musher, B. L., Goldberg, J., Al Baghdadi, T., Goodman, K. A., McWilliams, R. R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303269 · Cited by 492
Ogura, A., Konishi, T., Cunningham, C., Garcia-Aguilar, J., Iversen, H., Toda, S., Lee, I. K., Lee, H. X., Uehara, K., Lee, P., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00032 · Cited by 491
(2007) · Radiology · doi:10.1148/radiol.2431051825 · Cited by 490
Brændengen, M., Tveit, K. M., Berglund, Å., Birkemeyer, E., Frykholm, G., Påhlman, L., Wiig, J. N., Byström, P., Bujko, K., & Glimelius, B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.3858 · Cited by 476
Chau, I., Brown, G., Cunningham, D., Tait, D., Wotherspoon, A., Norman, A. R., Tebbutt, N., Hill, M., Ross, P. J., Massey, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4875 · Cited by 474
Smith, N. J., Barbachano, Y., Norman, A. R., Swift, R. I., Abulafi, A. M., & Brown, G. (2008) · Journal of British Surgery · doi:10.1002/bjs.5917 · Cited by 464
Fokas, E., Liersch, T., Fietkau, R., Hohenberger, W., Beissbarth, T., Hess, C., Becker, H., Ghadimi, M., Mrak, K., Merkel, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3769 · Cited by 454
“The design of the clinical trial, eligibility and exclusion criteria, treatment plan and long-term oncologic results have been reported in detail elsewhere.(3,4)”
BackgroundMethodInfluentialSelf-citationHabr-Gama, A., Perez, R. O., Wynn, G., Marks, J., Kessler, H., & Gama-Rodrigues, J. (2010) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181f42b89 · Cited by 454
Past, present, and future of radiotherapy for the benefit of patients
Thariat, J., Hannoun-Levi, J.-M., Sun Myint, A., Vuong, T., & Gérard, J.-P. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.203 · Cited by 455
Engstrom, P. F., Arnoletti, J. P., Benson, A. B., Chen, Y.-J., Choti, M. A., Cooper, H. S., Covey, A., Dilawari, R. A., Early, D. S., Enzinger, P. C., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0057 · Cited by 439
Capirci, C., Valentini, V., Cionini, L., De Paoli, A., Rodel, C., Glynne-Jones, R., Coco, C., Romano, M., Mantello, G., Palazzi, S., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.12.019 · Cited by 445
Self-citationCollette, L., Bosset, J.-F., den Dulk, M., Nguyen, F., Mineur, L., Maingon, P., Radosevic-Jelic, L., Piérart, M., & Calais, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9685 · Cited by 447
O'Connell, M. J., Colangelo, L. H., Beart, R. W., Petrelli, N. J., Allegra, C. J., Sharif, S., Pitot, H. C., Shields, A. F., Landry, J. C., Ryan, D. P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.7753 · Cited by 439
Buchs, N. C., Gervaz, P., Secic, M., Bucher, P., Mugnier-Konrad, B., & Morel, P. (2008) · International Journal of Colorectal Disease · doi:10.1007/s00384-007-0399-3 · Cited by 442
Fernández-Martos, C., Pericay, C., Aparicio, J., Salud, A., Safont, M., Massuti, B., Vera, R., Escudero, P., Maurel, J., Marcuello, E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8541 · Cited by 438
Chow, A., Tilney, H. S., Paraskeva, P., Jeyarajah, S., Zacharakis, E., & Purkayastha, S. (2009) · International Journal of Colorectal Disease · doi:10.1007/s00384-009-0660-z · Cited by 428
Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer
Gérard, J.-P., Azria, D., Gourgou-Bourgade, S., Martel-Lafay, I., Hennequin, C., Etienne, P.-L., Vendrely, V., François, E., de La Roche, G., Bouché, O., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8771 · Cited by 430
Pancreatic Cancer: A Review of Current Treatment and Novel Therapies
Kolbeinsson, H. M., Chandana, S., Wright, G. P., & Chung, M. (2023) · Journal of Investigative Surgery · doi:10.1080/08941939.2022.2129884 · Cited by 386
“Additionally, it has been shown to be better tolerated than adjuvant chemotherapy in other cancers, resulting in improved completion rates [63, 64].”
Nonoperative Management of Rectal Cancer With Complete Clinical Response After Neoadjuvant Therapy
Smith, J. D., Ruby, J. A., Goodman, K. A., Saltz, L. B., Guillem, J. G., Weiser, M. R., Temple, L. K., Nash, G. M., & Paty, P. B. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e3182759f1c · Cited by 418
“Our experience suggests that the critical factors for case selection are (1) to adopt highly stringent criteria for cCR based on digital examination and endoscopic visualization and (2) to defer final assessment of the favorably responding tumors for as long as 10 to 12 weeks after CRT so that tumors destined for pCR…”
Method2017 WSES guidelines on colon and rectal cancer emergencies: obstruction and perforation
Pisano, M., Zorcolo, L., Merli, C., Cimbanassi, S., Poiasina, E., Ceresoli, M., Agresta, F., Allievi, N., Bellanova, G., Coccolini, F., et al. (2018) · World Journal of Emergency Surgery · doi:10.1186/s13017-018-0192-3 · Cited by 396
Schrag, D., Weiser, M. R., Goodman, K. A., Gon̈en, M., Hollywood, E., Cercek, A., Reidy-Lagunes, D. L., Gollub, M. J., Shia, J., Guillem, J. G., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.7904 · Cited by 414
“rectal cancer therapeutics have been made including better surgical technique with TME and better imaging with CT, MRI, and ERUS, better chemotherapy regimens,(15) and optimal ways to deliver chemoradiotherapy.(3,4) Notwithstanding these advances, in recent trials, 25% of patients with locally advanced rectal cancer h…”
MethodEURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum
van de Velde, C. J. H., Boelens, P. G., Borras, J. M., Coebergh, J.-W., Cervantes, A., Blomqvist, L., Beets-Tan, R. G. H., van den Broek, C. B. M., Brown, G., Van Cutsem, E., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.048 · Cited by 404
“Up front resection followed by surveillance only, 5 5 radiation followed by immediate (2–3 days) surgery [156,157], chemoradiation (CRT) followed by delayed (6– 8 weeks) surgery [158,159].”
MethodSelf-citationDijkstra, E. A., Nilsson, P. J., Hospers, G. A. P., Bahadoer, R. R., Meershoek-Klein Kranenbarg, E., Roodvoets, A. G. H., Putter, H., Berglund, Å., Cervantes, A., Crolla, R. M. P. H., et al. (2023) · Annals of Surgery · doi:10.1097/sla.0000000000005799 · Cited by 390
Deng, Y., Chi, P., Lan, P., Wang, L., Chen, W., Cui, L., Chen, D., Cao, J., Wei, H., Peng, X., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6198 · Cited by 395
on behalf of the Rectal Cancer Consortium, Smith, J. J., Chow, O. S., Gollub, M. J., Nash, G. M., Temple, L. K., Weiser, M. R., Guillem, J. G., Paty, P. B., Avila, K., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1632-z · Cited by 391
“The study design is innovative because it compares 3-year DFS in a group of LARC patients treated according to a protocol incorporating TNT and NOM, to a similar group of historical controls treated according to the standard CRT, TME and ACT protocol.”
BackgroundInfluentialHabr-Gama, A., Perez, R. O., Proscurshim, I., Campos, F. G., Nadalin, W., Kiss, D., & Gama-Rodrigues, J. (2006) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2006.09.005 · Cited by 391
“In fact, prospective randomized trials have failed to demonstrate definitive survival benefit of this approach, possibly due to distant failure rates.(5,6) However, preoperative CRT has been shown to decrease circulating bone marrow micrometastases, suggesting a possible decrease (or delay) in tumor recurrence.”
BackgroundResultInfluentialRex, D. K., Kahi, C. J., Levin, B., Smith, R. A., Bond, J. H., Brooks, D., Burt, R. W., Byers, T., Fletcher, R. H., Hyman, N., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.013 · Cited by 392
Lambregts, D. M. J., Vandecaveye, V., Barbaro, B., Bakers, F. C. H., Lambrecht, M., Maas, M., Haustermans, K., Valentini, V., Beets, G. L., & Beets-Tan, R. G. H. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1607-5 · Cited by 390
Dewdney, A., Cunningham, D., Tabernero, J., Capdevila, J., Glimelius, B., Cervantes, A., Tait, D., Brown, G., Wotherspoon, A., Gonzalez de Castro, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6036 · Cited by 392
“systemic recurrence remains a significant problem, occurring in 30% to 40% of patients.(7,8)”
BackgroundKalady, M. F., de Campos-Lobato, L. F., Stocchi, L., Geisler, D. P., Dietz, D., Lavery, I. C., & Fazio, V. W. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181b91e63 · Cited by 386
“Several large prospective trials have demonstrated the benefits of chemotherapy and radiation in addition to surgery for locally advanced rectal cancer.(4,5) Furthermore, neoadjuvant compared with adjuvant delivery has been established as the standard of care for advanced rectal cancers in the lower two-thirds of the…”
BackgroundTie, J., Cohen, J. D., Wang, Y., Li, L., Christie, M., Simons, K., Elsaleh, H., Kosmider, S., Wong, R., Yip, D., et al. (2019) · Gut · doi:10.1136/gutjnl-2017-315852 · Cited by 381
Guillem, J. G., Chessin, D. B., Cohen, A. M., Shia, J., Mazumdar, M., Enker, W., Paty, P. B., Weiser, M. R., Klimstra, D., Saltz, L., et al. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000161980.46459.96 · Cited by 386
“A recently completed prospective randomized trial has demonstrated that preoperative CMT provides for superior sphincter preservation rates and local control when compared with postoperative CMT.(21) However, there was no significant difference in overall survival between the groups receiving preoperative and postoper…”
BackgroundInfluentialHong, Y. S., Nam, B.-H., Kim, K.-P., Kim, J. E., Park, S. J., Park, Y. S., Park, J. O., Kim, S. Y., Kim, T.-Y., Kim, J. H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70377-8 · Cited by 383
Colorectal cancer: From prevention to personalized medicine
Binefa, G. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i22.6786 · Cited by 382
Birgisson, H., Påhlman, L., Gunnarsson, U., & Glimelius, B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.9017 · Cited by 376
The multidisciplinary management of rectal cancer
Keller, D. S., Berho, M., Perez, R. O., Wexner, S. D., & Chand, M. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0275-y · Cited by 359
Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer
Anitei, M.-G., Zeitoun, G., Mlecnik, B., Marliot, F., Haicheur, N., Todosi, A.-M., Kirilovsky, A., Lagorce, C., Bindea, G., Ferariu, D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2830 · Cited by 358
Horvat, N., Veeraraghavan, H., Khan, M., Blazic, I., Zheng, J., Capanu, M., Sala, E., Garcia-Aguilar, J., Gollub, M. J., & Petkovska, I. (2018) · Radiology · doi:10.1148/radiol.2018172300 · Cited by 355
Mentha, G., Majno, P. E., Andres, A., Rubbia-Brandt, L., Morel, P., & Roth, A. D. (2006) · British Journal of Surgery · doi:10.1002/bjs.5346 · Cited by 356
Ghadimi, B. M., Grade, M., Difilippantonio, M. J., Varma, S., Simon, R., Montagna, C., Füzesi, L., Langer, C., Becker, H., Liersch, T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.406 · Cited by 348
Self-citationRectal and colon cancer: Not just a different anatomic site
Tamas, K., Walenkamp, A. M. E., de Vries, E. G. E., van Vugt, M. A. T. M., Beets-Tan, R. G., van Etten, B., de Groot, D. J. A., & Hospers, G. A. P. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.06.007 · Cited by 331
“9 Primary rectal cancer requires specific surgical treatment: total mesorectal excision (TME), 10 preceded by neoadjuvant radiotherapy or chemoradiotherapy [5,6].”
BackgroundDas, P., Skibber, J. M., Rodriguez‐Bigas, M. A., Feig, B. W., Chang, G. J., Wolff, R. A., Eng, C., Krishnan, S., Janjan, N. A., & Crane, C. H. (2007) · Cancer · doi:10.1002/cncr.22625 · Cited by 332
“late toxicity compared with patients who received postoperative chemoradiation.(1) Moreover, the German Intergroup trial demonPresented in part at the Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Philadelphia, Pennsylvania, November 5 9, 2006.”
BackgroundInfluentialPostoperative adjuvant chemotherapy in rectal cancer operated for cure.
Petersen, S. H., Harling, H., Kirkeby, L. T., Wille-Jørgensen, P., & Mocellin, S. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004078.pub2 · Cited by 326
The Challenges of Colorectal Cancer Survivorship
Denlinger, C. S., & Barsevick, A. M. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0058 · Cited by 324
“The use of chemoradiotherapy in rectal cancer has resulted in improved survival and local control (8, 9).”
Background
Metadata
- Authors
- Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., Karstens, J.-H., Liersch, T., Schmidberger, H., & Raab, R.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Leipzig University (DE)
- University of Rostock (DE)
- Charité – Universitätsmedizin Berlin (DE)
- Hospital of the Brothers of St. John of God (AT)
- Klinikum Klagenfurt (AT)
- University of Göttingen (DE)
- Medizinische Hochschule Hannover (DE)
- Klinikum Oldenburg (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-10-21
- Volume
- 351
- Issue
- 17
- Pages
- 1731-1740
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2125452425
- Cited by
- 6,050
- References
- 19
- Citations by year
- 2026: 178 · 2025: 205 · 2024: 232 · 2023: 275 · 2022: 310 · 2021: 324 · 2020: 322 · 2019: 321 · 2018: 305 · 2017: 298 · 2016: 291 · 2015: 348 · 2014: 340 · 2013: 333 · 2012: 346
- FWCI
- 82.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- GRO (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Colorectal and Anal Carcinomas
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Keywords
- rectal cancer, locally advanced rectal cancer, neoadjuvant chemoradiotherapy, postoperative chemoradiotherapy, neoadjuvant therapy, adjuvant therapy, 5-fluorouracil, boost radiotherapy, local recurrence, overall survival, treatment toxicity
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Combined Modality Therapy, Female, Fluorouracil, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Postoperative Care, Postoperative Complications, Preoperative Care, Quality Control, Radiotherapy, Rectal Neoplasms, Incidence, Proportional Hazards Models, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.